BackgroundMyocardial ischemia-reperfusion injury (MIRI) remains a significant challenge in treating cardiovascular diseases, contributing to substantial myocardial damage and a poor prognosis. Traditional Chinese medicine (TCM) offers promising alternatives, with Xuan Bi Tong Yu Fang (XBTYF) being a classical formula known for its protective effects.
However, the therapeutic mechanisms of XBTYF in MIRI have not been fully explored.Materials and methodsMIRI was induced in 36 Wistar rats, which were randomly assigned to sham, model, XBTYF (high, medium, low dose), and positive control (Qishen Yiqi Droplet) groups (n = 6). Serum levels of CK, AST, and cTnI were measured, and myocardial injury was examined by TTC, HE, and Masson staining.
Bulk RNA-seq was performed to analyze gene expression profiles. The chemical composition of XBTYF was characterized by UPLC-MS/MS, followed by molecular docking to assess interactions between key compounds and Hoxb4.
In vitro, H9C2 cardiomyocytes were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) and treated with XBTYF. The role of Hoxb4 in regulating the Wnt/β-catenin pathway was examined through gain- and loss-of-function approaches, together with the Wnt inhibitor IWR-1.
Frontiers in Immunology published a clinical update in Infectious Disease on 07 May 2026.
The item focuses on Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury.
Review the original article for the full source wording and details.